Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community. Your name, email, zip, and investor type is all it takes to open the door to research reports, favorites tracking, and virtual and in-person roadshows / conferences. Even exclusive investment opps.

Take it to the next level. It doesn’t cost a penny.

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

Chinese fast fashion juggernaut Shein has filed confidentially for an initial public offering in the U.S., positioning itself to become one of the most highly-anticipated public debuts. As Shein aims to expand its global empire and enormous valuation, the company will need to convince investors it can overcome mounting controversies.



Currently privately held with an estimated $66 billion valuation, Shein is seeking to capitalize on surging investor appetite for ecommerce platforms. By targeting Gen Z and millennial shoppers with on-trend fast fashion at rock-bottom prices, Shein has experienced explosive growth. The company could <a href="https://www.channelchek.com/news-channel/shein-sets-sights-on-90-billion-valuation-for-highly-anticipated-us-ipo">start trading publicly in the U.S. as early as 2024</a> if it gains regulatory approval.



Shein Hopes to Captivate Ecommerce Investors



As a digital-only retailer with minimal storefronts, Shein epitomizes many of today’s leading ecommerce firms. With targeted influencer marketing and constantly updated inventory, Shein has won over young consumers across the globe. Revenues reached nearly $16 billion in 2021, making Shein one of the largest fashion retailers based on sales.



This rapid ascent has drawn comparisons to platforms like Pinduoduo and Meituan in China. Shein hopes investors will value it similarly and overlook the controversies it has battled along the way. Skeptics, however, point to lingering risks that could limit Shein’s appeal.



Mounting Concerns Create Obstacles for Shein’s IPO



While Shein has taken steps to revamp public perception, the company faces no shortage of detractors. Lawmakers across the political spectrum have raised alarms over Shein’s supply chain and environmental harms.



Accused of using labor from China’s Xinjiang region linked to human rights abuses, Shein must convince regulators it complies with ethical sourcing standards. The shadowy leadership of founder and CEO Sky Xu also clashes with typical corporate governance. As other Chinese firms face heightened scrutiny and even delisting threats in the U.S., Shein’s close China ties could hamper its reception.



Alongside these issues, fast fashion business models face growing backlash for fueling waste and pollution. Though unlikely to vanish overnight, changing consumer preferences add uncertainty to the sector’s outlook.



Betting on Shein’s Growth Trajectory While risks abound, Shein’s blockbuster financials may simply be too impressive for investors to ignore. Early in its life as a public firm, revenue expansion and user growth will remain the key metrics to watch.



As a veteran of the ultra-fast fashion space, Shein has proven adept at riding waves of consumer demand. The recent downturn for stocks like Farfetch and Revolve point to lingering appetite for digital fashion platforms. Though controversies cast a shadow, for risk-tolerant investors, getting in early with Shein could bring substantial rewards.

Chinese fast fashion juggernaut Shein has filed confidentially for an initial public offering in the U.S., positioning itself to become one of the most highly-anticipated public debuts. As Shein aims to expand its global empire and enormous valuation, the company will need to convince investors it can overcome mounting controversies.



Currently privately held with an estimated $66 billion valuation, Shein is seeking to capitalize on surging investor appetite for ecommerce platforms. By targeting Gen Z and millennial shoppers with on-trend fast fashion at rock-bottom prices, Shein has experienced explosive growth. The company could start trading publicly in the U.S. as early as 2024 if it gains regulatory approval.



Shein Hopes to Captivate Ecommerce Investors



As a digital-only retailer with minimal storefronts, Shein epitomizes many of today’s leading ecommerce firms. With targeted influencer marketing and constantly updated inventory, Shein has won over young consumers across the globe. Revenues reached nearly $16 billion in 2021, making Shein one of the largest fashion retailers based on sales.



This rapid ascent has drawn comparisons to platforms like Pinduoduo and Meituan in China. Shein hopes investors will value it similarly and overlook the controversies it has battled along the way. Skeptics, however, point to lingering risks that could limit Shein’s appeal.



Mounting Concerns Create Obstacles for Shein’s IPO



While Shein has taken steps to revamp public perception, the company faces no shortage of detractors. Lawmakers across the political spectrum have raised alarms over Shein’s supply chain and environmental harms.



Accused of using labor from China’s Xinjiang region linked to human rights abuses, Shein must convince regulators it complies with ethical sourcing standards. The shadowy leadership of founder and CEO Sky Xu also clashes with typical corporate governance. As other Chinese firms face heightened scrutiny and even delisting threats in the U.S., Shein’s close China ties could hamper its reception.



Alongside these issues, fast fashion business models face growing backlash for fueling waste and pollution. Though unlikely to vanish overnight, changing consumer preferences add uncertainty to the sector’s outlook.



Betting on Shein’s Growth TrajectoryWhile risks abound, Shein’s blockbuster financials may simply be too impressive for investors to ignore. Early in its life as a public firm, revenue expansion and user growth will remain the key metrics to watch.



As a veteran of the ultra-fast fashion space, Shein has proven adept at riding waves of consumer demand. The recent downturn for stocks like Farfetch and Revolve point to lingering appetite for digital fashion platforms. Though controversies cast a shadow, for risk-tolerant investors, getting in early with Shein could bring substantial rewards.

Shein Files Confidentially for U.S. IPO, Seeks to Capture Investor Interest

Ecommerce

Fashion

Shein

Shopping

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Tuesday, November 28, 2023



Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Contract.&nbsp;Last week, Bit Digital announced details regarding its first Bit Digital AI contract.&nbsp;Under the terms of the agreement, Bit Digital will supply the customer with computational power from 1,504 GPUs for a period of three years. The contract will commence&nbsp;January 2024&nbsp;and represents more than&nbsp;$35 million&nbsp;of annualized revenue to Bit Digital.



Platform.&nbsp;To fulfill the contract, the Company placed a purchase order for servers manufactured by Super Micro Computer, Inc., an authorized Nvidia OEM, that are equipped with 1,504 Nvidia HGX H100 GPUs along with related equipment, which are expected to be delivered to the Company by&nbsp;January 2024.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/26291">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Tuesday, November 28, 2023



Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Contract.&nbsp;Last week, Bit Digital announced details regarding its first Bit Digital AI contract.&nbsp;Under the terms of the agreement, Bit Digital will supply the customer with computational power from 1,504 GPUs for a period of three years. The contract will commence&nbsp;January 2024&nbsp;and represents more than&nbsp;$35 million&nbsp;of annualized revenue to Bit Digital.



Platform.&nbsp;To fulfill the contract, the Company placed a purchase order for servers manufactured by Super Micro Computer, Inc., an authorized Nvidia OEM, that are equipped with 1,504 Nvidia HGX H100 GPUs along with related equipment, which are expected to be delivered to the Company by&nbsp;January 2024.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Bit Digital (BTBT) - Finalized AI Contract

Bit Digital

BTBT

Capital Markets

Financial Services

Noble Capital Markets Research Morning Call

With the U.S. government cracking down on Binance, <a href="https://www.channelchek.com/news-channel/binance-ceo-pleads-guilty-to-money-laundering">slapping the world’s largest cryptocurrency exchange with $4.3 billion in fines</a> and forcing its maverick founder Changpeng “CZ” Zhao to relinquish control, arch-rival Coinbase sees an opening to reclaim market share by playing the role of the "good guy" traded on Wall Street.



Coinbase shares have jumped some 18% over the past week to around $118 as CEO Brian Armstrong asserted last Tuesday’s settlement finally “closes that chapter of crypto’s history” in which Binance flouted global regulations while handling over $15 trillion in trades since 2017. By contrast, Armstrong now aims to position Nasdaq-listed Coinbase as the compliant, institutional exchange best positioned to capitalize on the crypto industry’s shift toward greater oversight.



“Building a company offshore, skirting regulation, it's just not going to work,” Armstrong told CNBC, taking a shot across the bow of both Binance as well as consumers who transacted on the exchange drawn by its swift listings of new – often risky – digital assets. With federal agencies now policing crypto’s “Wild West” era, Armstrong wants to reassure investors that Coinbase will work hand-in-hand with authorities, supporting his belief that crypto can operate by the same rules as traditional finance.



Whether such harmony emerges remains clouded by legal issues confronting Coinbase itself, including an ongoing SEC lawsuit filed last June. While Armstrong feels “very good” about Coinbase’s defense and his aim is full regulatory clarity, such certainty seems distant given bitcoin’s recent plunge marking another crypto winter. Nonetheless, the humbling of the industry’s one-time dominant exchange gives his company a momentary edge.



Binance’s astronomical rise represented a meteoric challenge to Coinbase’s early market supremacy following its 2012 launch and 2017 debut on public markets weeks before bitcoin hit a historic peak near $20,000. Former Bloomberg programmer and Tokyo Stock Exchange developer Changpeng Zhao founded Binance in Shanghai in 2017, developing technical capabilities allowing it to scale at warp speed by listing new cryptocurrencies faster than cautious Coinbase.



With an opaque corporate structure based initially in Asia and subsequently the Cayman Islands, Binance also dodged oversight as global regulators sounded alarms. But its explosive growth quickly afforded Zhao celebrity status as one of crypto’s biggest whales and most vocal proselytizers. Meanwhile, to keep pace with its insurgent rival now commanding the majority of trading volumes, Coinbase rushed to expand its offerings but continued adhering to compliance standards in order to maintain institutional investor confidence.



Yet as U.S. authorities targeted Binance last year with a series of harsh punitive actions, momentum swung back toward its compliant competitor. Both the CFTC and SEC ultimately launched suits against Zhao’s exchange for allegedly violating investor protection statutes, culminating in extensive settlement terms compromising Binance’s autonomy going forward. With its renegade era under CZ seemingly finished, Armstrong aims to leverage Coinbase’s head start collaborating openly with financial watchdogs.



Despite his bravado about closing an ignominious chapter for crypto, Armstrong must still confront lingering suspicions from regulators like the SEC about whether any exchanges can provide adequate investor protections around highly speculative digital assets. Coinbase itself has fought SEC assertions that it facilitated unregistered securities trades.



While the two suits differ, both target core business models questioning whether current legislation written before crypto’s advent can properly govern such technologies. Beyond exacting large fines, authorities want to slow crypto trading – putting platforms like Coinbase and Binance in an existential vice grip complicated by token assets’ fluctuation between currency and security classifications.



How Congress and agencies like the SEC ultimately delineate acceptable crypto activity under existing statutes or new legislation could determine which exchanges remain standing. Ironically victories could stem as much from legal ingenuity as technology innovation. But with Binance at least temporarily defanged, Coinbase remains well positioned to shape crypto’s second act blending Wall Street's institutional trust with Silicon Valley’s disruptive daring.



Clearly the crypto landscape entering 2024 stands on shifting sands, clouded by bitcoin’s swoon, regulatory turbulence and possible global recession. Yet should pioneer blockchain currencies and exchanges somehow emerge resilient, Coinbase sits ready to seize the market share boon a humbled Binance left on the table. After years sparring in crypto’s octagon, this match’s decision appears nearer – though mainstream adoption stays stubbornly out of reach.

With the U.S. government cracking down on Binance, slapping the world’s largest cryptocurrency exchange with $4.3 billion in fines and forcing its maverick founder Changpeng “CZ” Zhao to relinquish control, arch-rival Coinbase sees an opening to reclaim market share by playing the role of the &#8220;good guy&#8221; traded on Wall Street.



Coinbase shares have jumped some 18% over the past week to around $118 as CEO Brian Armstrong asserted last Tuesday’s settlement finally “closes that chapter of crypto’s history” in which Binance flouted global regulations while handling over $15 trillion in trades since 2017. By contrast, Armstrong now aims to position Nasdaq-listed Coinbase as the compliant, institutional exchange best positioned to capitalize on the crypto industry’s shift toward greater oversight.



“Building a company offshore, skirting regulation, it&#8217;s just not going to work,” Armstrong told CNBC, taking a shot across the bow of both Binance as well as consumers who transacted on the exchange drawn by its swift listings of new – often risky – digital assets. With federal agencies now policing crypto’s “Wild West” era, Armstrong wants to reassure investors that Coinbase will work hand-in-hand with authorities, supporting his belief that crypto can operate by the same rules as traditional finance.



Whether such harmony emerges remains clouded by legal issues confronting Coinbase itself, including an ongoing SEC lawsuit filed last June. While Armstrong feels “very good” about Coinbase’s defense and his aim is full regulatory clarity, such certainty seems distant given bitcoin’s recent plunge marking another crypto winter. Nonetheless, the humbling of the industry’s one-time dominant exchange gives his company a momentary edge.



Binance’s astronomical rise represented a meteoric challenge to Coinbase’s early market supremacy following its 2012 launch and 2017 debut on public markets weeks before bitcoin hit a historic peak near $20,000. Former Bloomberg programmer and Tokyo Stock Exchange developer Changpeng Zhao founded Binance in Shanghai in 2017, developing technical capabilities allowing it to scale at warp speed by listing new cryptocurrencies faster than cautious Coinbase.



With an opaque corporate structure based initially in Asia and subsequently the Cayman Islands, Binance also dodged oversight as global regulators sounded alarms. But its explosive growth quickly afforded Zhao celebrity status as one of crypto’s biggest whales and most vocal proselytizers. Meanwhile, to keep pace with its insurgent rival now commanding the majority of trading volumes, Coinbase rushed to expand its offerings but continued adhering to compliance standards in order to maintain institutional investor confidence.



Yet as U.S. authorities targeted Binance last year with a series of harsh punitive actions, momentum swung back toward its compliant competitor. Both the CFTC and SEC ultimately launched suits against Zhao’s exchange for allegedly violating investor protection statutes, culminating in extensive settlement terms compromising Binance’s autonomy going forward. With its renegade era under CZ seemingly finished, Armstrong aims to leverage Coinbase’s head start collaborating openly with financial watchdogs.



Despite his bravado about closing an ignominious chapter for crypto, Armstrong must still confront lingering suspicions from regulators like the SEC about whether any exchanges can provide adequate investor protections around highly speculative digital assets. Coinbase itself has fought SEC assertions that it facilitated unregistered securities trades.



While the two suits differ, both target core business models questioning whether current legislation written before crypto’s advent can properly govern such technologies. Beyond exacting large fines, authorities want to slow crypto trading – putting platforms like Coinbase and Binance in an existential vice grip complicated by token assets’ fluctuation between currency and security classifications.



How Congress and agencies like the SEC ultimately delineate acceptable crypto activity under existing statutes or new legislation could determine which exchanges remain standing. Ironically victories could stem as much from legal ingenuity as technology innovation. But with Binance at least temporarily defanged, Coinbase remains well positioned to shape crypto’s second act blending Wall Street&#8217;s institutional trust with Silicon Valley’s disruptive daring.



Clearly the crypto landscape entering 2024 stands on shifting sands, clouded by bitcoin’s swoon, regulatory turbulence and possible global recession. Yet should pioneer blockchain currencies and exchanges somehow emerge resilient, Coinbase sits ready to seize the market share boon a humbled Binance left on the table. After years sparring in crypto’s octagon, this match’s decision appears nearer – though mainstream adoption stays stubbornly out of reach.

Coinbase Aims for Crypto Crown as Binance Stumbles

Binance

Blockchain

Coinbase

Crypto

Cryptocurrency

<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/ktos-logo-pr.png" alt="" class="wp-image-49245"/></figure>



<a href="http://www.channelchek.com/company/ktos">Research News and Market Data on KTOS </a>



November 27, 2023 at 8:00 AM EST



Target Systems Included BQM Cruise Missile and Short-Range Aegis Readiness Assessment Vehicles



SAN DIEGO,&nbsp;Nov. 27, 2023&nbsp;(GLOBE NEWSWIRE) --&nbsp;Kratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ: KTOS), a&nbsp;Technology Company&nbsp;in the Defense, National Security and Global Markets, announced today that its Defense &amp; Rocket Systems business supported the successful&nbsp;<a href="https://www.globenewswire.com/Tracker?data=J2rc9GxBKimZ0ONQ5mRgTDtCNfsQ99n9-8M5O4xVp0VFSvKLAu3mI-xREY41iRm2Hd1zZ_sWlydd48MHGg0E9PyM52XctwbjuROYquS-U_G0uxp5Q1t3zz7LJcZHox_xEArl2H-LUcxvKdEsIvK35anceKR0-M0UQdflEcwRz2nmwmI_ctZAvXjh5hl4ZQiYaoevE4ORthCyz0eS9VRsABrwhfntwtty6V2yrTju2yNBPISABRT_cLsbH6AZrLl4" target="_blank" rel="noreferrer noopener">intercept test of two Short-Range Ballistic Missile (SRBM) targets</a>, known as Aegis Readiness Assessment Vehicle (ARAV) by two Standard Missile 3 Block IA (SM-3 Blk IA) interceptors during the test event Vigilant Wyvern, also known as Flight Test Aegis Weapon System-48 (FTM-48). The successful test demonstrated the capability of a ballistic missile defense-configured Aegis ship to detect, track, engage and execute intercepts of two SRBM targets while concurrently demonstrating an Anti-Air Warfare (AAW) engagement of two subsonic anti-ship cruise missile drone targets. This live-fire, raid scenario represented one of the largest&nbsp;Integrated Air&nbsp;and Missile Defense (IAMD) events ever conducted in the&nbsp;U.S.&nbsp;Indo-Pacific Command Area of Responsibility and demonstrated for the first time a concurrent Ballistic Missile Defense and Anti-Air Warfare raid.



The successful intercepts by the Arleigh Burke-class destroyer&nbsp;USS CARL M. LEVIN&nbsp;(DDG 120) were the highlight of the Vigilant Wyvern/FTM-48 event and the culmination of a four-week campaign during which Kratos Rocket Systems business, along with its government and industry partners, integrated and launched the two SRBM targets from the Pacific Missile Range Facility (PMRF) in&nbsp;Hawaii. Both ARAV target systems, which have a long-standing, successful, flight-demonstrated heritage on test and intercept missions for the&nbsp;U.S. Navy&nbsp;and MDA, executed nominal trajectories while meeting target requirements.



“Our team works side-by-side with our government customers to deliver transformative and affordable target systems and vehicles from mission inception through successful launch operations.&nbsp;FTM-48, which was one of our largest recent mission campaigns, is just the latest example of this successful partnership,” said&nbsp;Dave Carter, President of Kratos Rocket Systems Division. “Kratos’ affordable systems allow our customers to cost effectively effect multi system raid scenarios like Vigilant Wyvern, and we are grateful to be able to continue supporting the&nbsp;U.S.&nbsp;DoD&nbsp;and its allies in this very important mission area.”



The BQM is a sub-sonic aerial target, capable of speeds greater than .09 Mach and minimum altitude of 6.6 feet, and has no equal when it comes to delivering realistic anti-ship missile threat emulation.



Kratos is a leading provider of products, solutions, and services supporting ballistic missile defense for Aegis Weapon System, hypersonic testing, atmospheric science research and technology maturation.



About&nbsp;Kratos Defense &amp; Security Solutions Kratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ: KTOS) is a technology company that develops and fields transformative, affordable systems, products, and solutions for United States National Security, our allies, and global commercial enterprises. At Kratos, Affordability is a Technology, and Kratos is changing the way breakthrough technology is rapidly brought to market – at a low cost – with actual products, systems, and technologies rather than slide decks or renderings. Through proven commercial and venture capital-backed approaches, including proactive, internally funded research and streamlined development processes, Kratos is focused on being First to Market with our solutions well in advance of the competition. Kratos is the recognized Technology Disruptor in our core market areas, including&nbsp;Space and Satellite Communications, Cyber Security and Warfare, Unmanned Systems, Rocket and Hypersonic Systems, Next-Generation Jet Engines and Propulsion Systems,&nbsp;Microwave Electronics, C5ISR, and Virtual and Augmented Reality Training Systems. For more information go to&nbsp;<a href="https://www.globenewswire.com/Tracker?data=nSxRHoptfK2lO8rPI6JzH_w3n7cEEV8StRJyQodZKP8UcSCS9NKvZm-LF9UK2eqPWOmWy_lYxx9lUFT5gFDZ1g_Tv0rAPXDEFIoME5T_Jcw=" target="_blank" rel="noreferrer noopener">www.KratosDefense.com</a>.



Notice Regarding Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made based on the current beliefs, expectations, and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended&nbsp;December 25, 2022, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the&nbsp;SEC&nbsp;by Kratos.



Press Contact: Yolanda White 858-812-7302 Direct



Investor Information: 877-934-4687 <a href="https://www.globenewswire.com/Tracker?data=Vg9qZem31LUdYOsS37RB4qnTHjRFWEhb3MxT7gI0U7-LUdVmGo6OJ3PeuumUMei3uHCE6fu2OTUQfrJB_zNWO-N6cET0DO3giqwpAHUgnrRYsRQtUfT0zYNE9WNT28Cw" target="_blank" rel="noreferrer noopener">investor@kratosdefense.com</a>



<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ceb2d2ff-c6fb-4d11-a8bf-055bddb97f84"></a>



Source: Kratos Defense &amp; Security Solutions, Inc.

Research News and Market Data on KTOS 



November 27, 2023 at 8:00 AM EST



Target Systems Included BQM Cruise Missile and Short-Range Aegis Readiness Assessment Vehicles



SAN DIEGO,&nbsp;Nov. 27, 2023&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;Kratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ: KTOS), a&nbsp;Technology Company&nbsp;in the Defense, National Security and Global Markets, announced today that its Defense &amp; Rocket Systems business supported the successful&nbsp;intercept test of two Short-Range Ballistic Missile (SRBM) targets, known as Aegis Readiness Assessment Vehicle (ARAV) by two Standard Missile 3 Block IA (SM-3 Blk IA) interceptors during the test event Vigilant Wyvern, also known as Flight Test Aegis Weapon System-48 (FTM-48). The successful test demonstrated the capability of a ballistic missile defense-configured Aegis ship to detect, track, engage and execute intercepts of two SRBM targets while concurrently demonstrating an Anti-Air Warfare (AAW) engagement of two subsonic anti-ship cruise missile drone targets. This live-fire, raid scenario represented one of the largest&nbsp;Integrated Air&nbsp;and Missile Defense (IAMD) events ever conducted in the&nbsp;U.S.&nbsp;Indo-Pacific Command Area of Responsibility and demonstrated for the first time a concurrent Ballistic Missile Defense and Anti-Air Warfare raid.



The successful intercepts by the Arleigh Burke-class destroyer&nbsp;USS CARL M. LEVIN&nbsp;(DDG 120) were the highlight of the Vigilant Wyvern/FTM-48 event and the culmination of a four-week campaign during which Kratos Rocket Systems business, along with its government and industry partners, integrated and launched the two SRBM targets from the Pacific Missile Range Facility (PMRF) in&nbsp;Hawaii. Both ARAV target systems, which have a long-standing, successful, flight-demonstrated heritage on test and intercept missions for the&nbsp;U.S. Navy&nbsp;and MDA, executed nominal trajectories while meeting target requirements.



“Our team works side-by-side with our government customers to deliver transformative and affordable target systems and vehicles from mission inception through successful launch operations.&nbsp;FTM-48, which was one of our largest recent mission campaigns, is just the latest example of this successful partnership,” said&nbsp;Dave Carter, President of Kratos Rocket Systems Division. “Kratos’ affordable systems allow our customers to cost effectively effect multi system raid scenarios like Vigilant Wyvern, and we are grateful to be able to continue supporting the&nbsp;U.S.&nbsp;DoD&nbsp;and its allies in this very important mission area.”



The BQM is a sub-sonic aerial target, capable of speeds greater than .09 Mach and minimum altitude of 6.6 feet, and has no equal when it comes to delivering realistic anti-ship missile threat emulation.



Kratos is a leading provider of products, solutions, and services supporting ballistic missile defense for Aegis Weapon System, hypersonic testing, atmospheric science research and technology maturation.



About&nbsp;Kratos Defense &amp; Security SolutionsKratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ: KTOS) is a technology company that develops and fields transformative, affordable systems, products, and solutions for United States National Security, our allies, and global commercial enterprises. At Kratos, Affordability is a Technology, and Kratos is changing the way breakthrough technology is rapidly brought to market – at a low cost – with actual products, systems, and technologies rather than slide decks or renderings. Through proven commercial and venture capital-backed approaches, including proactive, internally funded research and streamlined development processes, Kratos is focused on being First to Market with our solutions well in advance of the competition. Kratos is the recognized Technology Disruptor in our core market areas, including&nbsp;Space and Satellite Communications, Cyber Security and Warfare, Unmanned Systems, Rocket and Hypersonic Systems, Next-Generation Jet Engines and Propulsion Systems,&nbsp;Microwave Electronics, C5ISR, and Virtual and Augmented Reality Training Systems. For more information go to&nbsp;www.KratosDefense.com.



Notice Regarding Forward-Looking StatementsCertain statements in this press release may constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made based on the current beliefs, expectations, and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended&nbsp;December 25, 2022, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the&nbsp;SEC&nbsp;by Kratos.



Press Contact:Yolanda White858-812-7302 Direct



Investor Information:877-934-4687investor@kratosdefense.com







Source: Kratos Defense &amp; Security Solutions, Inc.

Release - Kratos Supports Successful US Navy and MDA Intercept Test Against Multiple Ballistic Missile and Anti-Ship Cruise Missile Targets

Defense

Kratos Defense &amp; Security

KTOS

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/03/dlhc_logo.png" alt="" class="wp-image-7337" style="width:158px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/dlhc">Research News and Market Data on DLHC</a>



November 27, 2023



ATLANTA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, will release financial results for its fiscal fourth quarter ended&nbsp;September 30, 2023 on December 6, 2023 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, December 7, 2023, during which members of senior management will make a brief presentation focused on&nbsp;the financial results and operating trends. A question-and-answer session will follow.&nbsp;



Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.&nbsp; Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call.&nbsp;A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 4720443.



About DLH DLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 3,200 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=mr_3Z2QbpjCxLX1xq6YJbf17gGaAly4PBxqxH_iiPYzkXZv3s7p5C5nj_AqTkNmHtlfXLrivEiWREeEK2frJLdpirLGvQ4t1egbDQqPQl2Q=" target="_blank" rel="noreferrer noopener">http://www.DLHcorp.com</a>.



INVESTOR RELATIONS Contact: Chris Witty Phone: 646-438-9385 Email: cwitty@darrowir.com

Research News and Market Data on DLHC



November 27, 2023



ATLANTA, Nov. 27, 2023 (GLOBE NEWSWIRE) &#8212; DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, will release financial results for its fiscal fourth quarter ended&nbsp;September 30, 2023 on December 6, 2023 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, December 7, 2023, during which members of senior management will make a brief presentation focused on&nbsp;the financial results and operating trends. A question-and-answer session will follow.&nbsp;



Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.&nbsp; Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call.&nbsp;A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 4720443.



About DLHDLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 3,200 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit&nbsp;http://www.DLHcorp.com.



INVESTOR RELATIONSContact: Chris WittyPhone: 646-438-9385Email: cwitty@darrowir.com

Release - DLH to Announce Fiscal 2023 Fourth Quarter Financial Results

DLH Holdings Corp.

DLHC

Government Solutions

<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1.png" alt="" class="wp-image-49026"/></figure>



<a href="http://www.channelchek.com/company/cocp">Research News and Market Data on COCP </a>



NOVEMBER 27, 2023



BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) --&nbsp;Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th&nbsp;Annual&nbsp;<a href="https://www.globenewswire.com/Tracker?data=0o9ilxpiKVsFWrWIzVSiXsunnwEJLgtalHlw1UIeQV9eM9_PJNAW6E6n17T_iaRidum2jMucCqzqizYxcrBU1Smip_hQGd21tKPudjabCu8=" target="_blank" rel="noreferrer noopener">Emerging Growth Equity Conference</a>&nbsp;on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.



“The coming year promises to be highly eventful with data expected from several of our antiviral development programs,” said Mr. Martin. “We are actively enrolling subjects in a Phase 1 clinical trial with our oral potent pan-coronavirus and pan-norovirus protease inhibitor CDI-988. With a Phase 2a human challenge clinical trial of our oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A, we are on track to begin dosing subjects in the very near term. We look forward to keeping our shareholders updated and sharing near-term milestones at NobleCon 19 and future investment conferences.”



A webcast of the Cocrystal presentation will be available beginning December 5 on the Company’s&nbsp;<a href="https://www.globenewswire.com/Tracker?data=7mUN-RgdSYCzwytwsYba6ZFRTy3P7gzeCBkgUGBmfM_4ufJaKfsdnV0Md7dgQqo47WXgiZeJb3rGdDMTvywu0XN9b4HHMY5oeyrNpBagfbo=" target="_blank" rel="noreferrer noopener">website</a>&nbsp;and will be archived for 90 days following the event.



About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=h4uexEJP2AOCgjnXQr0-I9ZUOeRqrWgvWaULkXQRpxSEoDzYbGG3_msdhXGT7Z5oSuBN207KXblTbgK-Li63gE-STGDtJREzYtEnMsGtkWM=" target="_blank" rel="noreferrer noopener">www.cocrystalpharma.com</a>.



Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the initiation and expected data from the Company’s antiviral development programs for CC-42344 as a product candidate for oral treatment of influenza A and CC-988 for oral treatment of coronavirus and norovirus. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks relating to the manufacturing and research delays arising from labor shortages and other factors, the ability of our Clinical Research Organization partners to recruit volunteers for, and to proceed with, clinical trials, and general risks arising from or involved in conducting clinical studies for CC-988 and CC-42344, including the results of such studies. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact: LHA Investor Relations Jody Cain 310-691-7100 <a href="https://www.globenewswire.com/Tracker?data=hPA0m-_yr6Y_nlLsV5N7yPfZCK8c6jhwVRXS7HEbiBWiiZxk11h_VrpUbq0zFRBC5ojaqN1Iq3yPIDWTBKC5Hw==" target="_blank" rel="noreferrer noopener">jcain@lhai.com</a>



Media Contact: JQA Partners Jules Abraham 917-885-7378 <a href="https://www.globenewswire.com/Tracker?data=-Wq9lW6mLWQxNmtLiJz97qTiIP-xK8QdyXkbOLqtbZ8Ny13msjJJl92i7I2ODYr56bIt2VBZj7tQU-_rCFLMk1gACHGeHmDV07yzrzavt_o=" target="_blank" rel="noreferrer noopener">Jabraham@jqapartners.com</a>



# # #<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ba04b6e2-72b0-4133-a46c-65bef5061ea4"></a>



Source: Cocrystal Pharma, Inc.



Released November 27, 2023

Research News and Market Data on COCP 



NOVEMBER 27, 2023



BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) &#8212;&nbsp;Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th&nbsp;Annual&nbsp;Emerging Growth Equity Conference&nbsp;on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.



“The coming year promises to be highly eventful with data expected from several of our antiviral development programs,” said Mr. Martin. “We are actively enrolling subjects in a Phase 1 clinical trial with our oral potent pan-coronavirus and pan-norovirus protease inhibitor CDI-988. With a Phase 2a human challenge clinical trial of our oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A, we are on track to begin dosing subjects in the very near term. We look forward to keeping our shareholders updated and sharing near-term milestones at NobleCon 19 and future investment conferences.”



A webcast of the Cocrystal presentation will be available beginning December 5 on the Company’s&nbsp;website&nbsp;and will be archived for 90 days following the event.



About Cocrystal Pharma, Inc.Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit&nbsp;www.cocrystalpharma.com.



Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the initiation and expected data from the Company’s antiviral development programs for CC-42344 as a product candidate for oral treatment of influenza A and CC-988 for oral treatment of coronavirus and norovirus. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks relating to the manufacturing and research delays arising from labor shortages and other factors, the ability of our Clinical Research Organization partners to recruit volunteers for, and to proceed with, clinical trials, and general risks arising from or involved in conducting clinical studies for CC-988 and CC-42344, including the results of such studies. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact:LHA Investor RelationsJody Cain310-691-7100jcain@lhai.com



Media Contact:JQA PartnersJules Abraham917-885-7378Jabraham@jqapartners.com



# # #



Source: Cocrystal Pharma, Inc.



Released November 27, 2023

Release - Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Biotechnology

COCP

Cocrystal Pharma

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Monday, November 27, 2023



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Board appointment.&nbsp;Mr. Kiran Patankar has been appointed President and Chief Executive Officer and has joined the company’s Board of Directors. He has served as Interim President and Chief Executive Officer since August. Mr. Patankar has led the execution of Maple Gold’s updated corporate strategy, which includes a detailed assessment of the company’s district-scale projects. We believe he will reshape the company into a leaner and more focused entity with an emphasis on value-added exploration.



Reining in costs.&nbsp;In 2020, 2021, and 2022, Maple Gold’s general and administrative expenses were C$3.0 million, C$4.9 million, and C$5.9 million, respectively, and C$2.8 million for the first six months of 2023. Third quarter G&amp;A expenses were $0.4 million. Based on third quarter financials, Mr. Patankar is making excellent progress reducing corporate overhead costs. As the operating partner, we expect the company to be judicious with its capital and that of its joint venture partner, Agnico Eagle Mines. As of September 30, Maple Gold Mines reported cash and cash equivalents amounting to C$4.4 million and marketable securities amounting to C$336.4 thousand. Approximately $6.0 million of Douay-Joutel joint venture funding remains available through January 2025 from Agnico Eagle.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/26297">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Monday, November 27, 2023



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Board appointment.&nbsp;Mr. Kiran Patankar has been appointed President and Chief Executive Officer and has joined the company’s Board of Directors. He has served as Interim President and Chief Executive Officer since August. Mr. Patankar has led the execution of Maple Gold’s updated corporate strategy, which includes a detailed assessment of the company’s district-scale projects. We believe he will reshape the company into a leaner and more focused entity with an emphasis on value-added exploration.



Reining in costs.&nbsp;In 2020, 2021, and 2022, Maple Gold’s general and administrative expenses were C$3.0 million, C$4.9 million, and C$5.9 million, respectively, and C$2.8 million for the first six months of 2023. Third quarter G&amp;A expenses were $0.4 million. Based on third quarter financials, Mr. Patankar is making excellent progress reducing corporate overhead costs. As the operating partner, we expect the company to be judicious with its capital and that of its joint venture partner, Agnico Eagle Mines. As of September 30, Maple Gold Mines reported cash and cash equivalents amounting to C$4.4 million and marketable securities amounting to C$336.4 thousand. Approximately $6.0 million of Douay-Joutel joint venture funding remains available through January 2025 from Agnico Eagle.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Maple Gold Mines (MGMLF) - Looking Ahead

Basic Materials

Maple Gold Mines

MGMLF

Natural Resources

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Monday, November 27, 2023



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Impressive DLE test work results. Results from bench-scale G2L Greenview direct lithium extraction (DLE) test work on brine from LithiumBank’s Boardwalk lithium brine project produced a high-purity concentrated brine, or eluate, with lithium concentrations between 3,000 and 7,000 milligrams per liter with greater than 98% recovery of lithium from the brine and low levels of impurities.



Potential to reduce project operating costs.&nbsp;Lower cost reagents used in the G2L DLE processing are approximately a third of the cost of those used in the DLE process that was used in the company’s maiden Boardwalk PEA published in May 2023. The results are expected to be included in an updated Boardwalk PEA expected in late 2023.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/26300">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Monday, November 27, 2023



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Impressive DLE test work results. Results from bench-scale G2L Greenview direct lithium extraction (DLE) test work on brine from LithiumBank’s Boardwalk lithium brine project produced a high-purity concentrated brine, or eluate, with lithium concentrations between 3,000 and 7,000 milligrams per liter with greater than 98% recovery of lithium from the brine and low levels of impurities.



Potential to reduce project operating costs.&nbsp;Lower cost reagents used in the G2L DLE processing are approximately a third of the cost of those used in the DLE process that was used in the company’s maiden Boardwalk PEA published in May 2023. The results are expected to be included in an updated Boardwalk PEA expected in late 2023.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

LithiumBank Resources (LBNKF) - Favorable DLE Test Results Bode Well for Boardwalk PEA

Industrial Metals &amp; Mining

LBNKF

LithiumBank Resources

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Monday, November 27, 2023



Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Moving to Market Perform.&nbsp;With the shares exceeding our recently instituted $13 price target, we are lowering our rating to Market Perform from Outperform. While we remain impressed with operating results, we believe a good portion of the recent share performance is being driven in anticipation of a sale of the Company, which we do not believe is imminent.



Stock Performance. LWAY shares are up 82% since closing at $9.38 on November 13th. While we believe the sell off in the shares following strong operating results was unwarranted, the subsequent price rebound has exceeded our $13 price target. To maintain an Outperform rating, our PT would need to exceed $19.50, which we believe would have LWAY shares "priced to perfection" from an operating standpoint, which, given the uncertain state of the economy, is a stretch in our view.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/26296">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Monday, November 27, 2023



Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Moving to Market Perform.&nbsp;With the shares exceeding our recently instituted $13 price target, we are lowering our rating to Market Perform from Outperform. While we remain impressed with operating results, we believe a good portion of the recent share performance is being driven in anticipation of a sale of the Company, which we do not believe is imminent.



Stock Performance. LWAY shares are up 82% since closing at $9.38 on November 13th. While we believe the sell off in the shares following strong operating results was unwarranted, the subsequent price rebound has exceeded our $13 price target. To maintain an Outperform rating, our PT would need to exceed $19.50, which we believe would have LWAY shares &#8220;priced to perfection&#8221; from an operating standpoint, which, given the uncertain state of the economy, is a stretch in our view.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;